Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II, Placebo Controlled Trial of Abacavir (ABC, 1592U89) in Combination With Open-Label Indinavir Sulfate (IDV) and Efavirenz (EFV, DMP-266) in HIV-Infected Subjects With Nucleoside Analog Experience: A Rollover Study for ACTG 320

NCT00001086 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00001086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II, Placebo Controlled Trial of Abacavir (ABC, 1592U89) in Combination With Open-Label Indinavir Sulfate (IDV) and Efavirenz (EFV, DMP-266) in HIV-Infected Subjects With Nucleoside Analog Experience: A Rollover Study for ACTG 320
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
September 30, 1999
Enrollment
300
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections